IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of cash flow

in CHF 1 000

 

Notes

 

01.01.–30.09.2023

 

01.01.–30.09.2022

Cash flows from operating activities

 

 

 

 

 

 

Proceeds from sales of securities

 

3

 

303 675

 

455 156

Purchase of securities

 

3

 

(56 602)

 

(129 226)

Interest receipts

 

 

 

17

 

Payments for services

 

 

 

(27 810)

 

(34 407)

Income taxes paid

 

 

 

(76)

 

(97)

Total cash flows from operating activities

 

 

 

219 204

 

291 426

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Dividend

 

 

 

(156 311)

 

(212 242)

Purchase of treasury shares

 

5

 

 

(27 303)

Repayment of borrowings

 

4

 

(60 900)

 

(52 000)

Interest payments

 

 

 

(4 219)

 

(949)

Total cash flows from financing activities

 

 

 

(221 430)

 

(292 494)

 

 

 

 

 

 

 

Foreign exchange difference

 

 

 

600

 

1 258

Change in cash and cash equivalents

 

 

 

(1 626)

 

190

 

 

 

 

 

 

 

Cash and cash equivalents at the beginning of the period

 

 

 

1 948

 

2 835

 

 

 

 

 

 

 

Cash and cash equivalents at the end of the period

 

 

 

322

 

3 025

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer